0000950170-24-003466.txt : 20240109 0000950170-24-003466.hdr.sgml : 20240109 20240109185231 ACCESSION NUMBER: 0000950170-24-003466 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240105 FILED AS OF DATE: 20240109 DATE AS OF CHANGE: 20240109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Townsend Richard Nolan CENTRAL INDEX KEY: 0001995218 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41855 FILM NUMBER: 24524480 MAIL ADDRESS: STREET 1: C/O LEXEO THERAPEUTICS, INC. STREET 2: 345 PARK AVENUE SOUTH, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lexeo Therapeutics, Inc. CENTRAL INDEX KEY: 0001907108 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 854012572 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 547-9879 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 4 1 ownership.xml 4 X0508 4 2024-01-05 0001907108 Lexeo Therapeutics, Inc. LXEO 0001995218 Townsend Richard Nolan C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK NY 10010 true true false false Chief Executive Officer true Common Stock 2024-01-05 4 A false 43750 0 A 170695 D Stock Option (Right to Buy) 14.48 2024-01-05 4 A false 262500 0 A 2034-01-04 Common Stock 262500 262500 D The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2025, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date. Total represents 126,945 shares of Common Stock and 43,750 RSUs. 25% of the shares underlying the option shall vest on January 5, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service. /s/ Jenny Robertson, Attorney-in-Fact 2024-01-09